Collaboration to Develop a Universal Influenza Vaccine Candidate
Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant
-Currently no approved universal influenza vaccine
-CDC estimates 35.5 million people were infected with influenza in U.S. during 2018-2019 season
-Mount Sinai’s current work in this area is funded under a contract award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), as part of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program established by NIAID.
-The development program will support an Investigational New Drug (IND) application for Phase I clinical trials.
finance.yahoo.com/ne...ation-124010661.html
-Currently no approved universal influenza vaccine
-CDC estimates 35.5 million people were infected with influenza in U.S. during 2018-2019 season
-Mount Sinai’s current work in this area is funded under a contract award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), as part of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program established by NIAID.
-The development program will support an Investigational New Drug (IND) application for Phase I clinical trials.
finance.yahoo.com/ne...ation-124010661.html